Business Context and Reporting Period
Heron Therapeutics, Inc. (HRTX) is a commercial-stage biotechnology company focused on acute care and oncology products, including ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is an accelerated filer with 189,279,369 shares of common stock outstanding as of May 6, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Product Sales | $34.7 million | $38.9 million |
| Gross Profit | $24.1 million | $30.4 million |
| Gross Margin | 69.4% | 78.3% |
| Net Loss | $(8.1) million | $2.6 million (Income) |
| Diluted EPS | $(0.04) | $0.01 |
| Cash & Short-Term Investments | $44.8 million | $46.6 million |
| Total Debt (Carrying Value) | $141.6 million | N/A (Prior structure) |
| Operating Cash Flow | $(1.5) million | $(8.9) million |
Material Changes vs. Prior Period
- Revenue Decline: Net product sales decreased 10.8% to $34.7 million. While Acute Care sales (ZYNRELEF, APONVIE) increased 32.3% due to market share gains, Oncology sales (CINVANTI, SUSTOL) dropped 26.3% due to lower unit volumes.
- Profitability Shift: The company reported a net loss of $8.1 million compared to net income of $2.6 million in Q1 2025. This was driven by a 16.2% increase in Sales and Marketing expenses and a 25.8% increase in Cost of Product Sales (COPs).
- Margin Compression: Gross margin declined to 69.4% from 78.3%. The increase in COPs was attributed to $0.3 million in inventory write-offs and a $1.9 million increase in unit costs due to supplier mix changes.
- Debt Restructuring Impact: Interest expense increased significantly due to the refinancing of the Working Capital Facility in August 2025 and the issuance of 2031 Convertible Notes. The 2026 Convertible Notes were fully extinguished in August 2025.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and short-term investments ($44.8 million) are sufficient to fund operations for at least one year from the filing date.
- Regulatory & Reimbursement: ZYNRELEF and APONVIE secured permanent J-codes from CMS effective April 1, 2025, and April 1, 2026, respectively, ensuring separate Medicare reimbursement outside surgical bundles.
- Legal Proceedings: The company is actively defending patent litigation regarding CINVANTI and APONVIE. Notable developments include a favorable court ruling against Fresenius Kabi (delaying generic approval to 2035) and settlements with Mylan and Qilu delaying generic entry to 2032. Litigation with Azurity (Slayback) regarding CINVANTI is ongoing with closing arguments held in March 2026.
- Nasdaq Compliance Risk: The company disclosed that its stock price failed to meet the $1.00 minimum bid price requirement for 27 consecutive business days (March 10 – April 16, 2026). It is currently in a compliance period to regain listing status.
- Geopolitical Risks: The filing highlights risks related to potential 100% tariffs on imported patented pharmaceuticals under Section 232 investigations, which could impact supply chains and costs.
Investor Verification Checklist
- Verify the status of the Nasdaq delisting notice and the company's plan to regain compliance with the $1.00 minimum bid price.
- Monitor the outcome of the pending CINVANTI litigation against Azurity (Slayback), as a loss could accelerate generic competition.
- Assess the sustainability of the 26.3% decline in Oncology sales and the company's strategy to reverse this trend.
- Review the impact of the new Working Capital Facility covenants (minimum cash, revenue, and EBITDA) on future operational flexibility.
- Confirm the timeline for the new Cary, North Carolina office lease commencement (expected May 25, 2026) and associated costs.